Norstella Launches Pipeline-to-Patient Productivity Index to Benchmark Biopharma Performance Across the Drug Development Lifecycle
CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder
Humacyte - CW27 | 10-K: FY2025 Revenue: USD 2.038 M
Humacyte - CW27 | 10-Q: FY2025 Q3 Revenue: USD 753 K
Humacyte - CW27 | 8-K: FY2025 Q3 Revenue: USD 753 K
Humacyte - CW27 | 10-Q: FY2025 Q2 Revenue: USD 301 K